Abstract 17b-Estradiol (E2) attenuates hypoxia-induced pulmonary hypertension (HPH) through estrogen receptor (ER)-dependent effects, including inhibition of hypoxia-induced endothelial cell proliferation; however, the mechanisms responsible for this remain unknown. We hypothesized that the protective effects of E2 in HPH are mediated through hypoxia-inducible factor 1a (HIF-1a)-dependent increases in ERb expression. Sprague-Dawley rats and ERa or ERb knockout mice were exposed to hypobaric hypoxia for 2-3 weeks. The effects of hypoxia were also studied in primary rat or human pulmonary artery endothelial cells (PAECs). Hypoxia increased expression of ERb, but not ERa, in lungs from HPH rats as well as in rat and human PAECs. ERb mRNA time dependently increased in PAECs exposed to hypoxia. Normoxic HIF-1a/HIF-2a stabilization increased PAEC ERb, whereas HIF-1a knockdown decreased ERb abundance in hypoxic PAECs. In turn, ERb knockdown in hypoxic PAECs increased HIF-2a expression, suggesting a hypoxia-sensitive feedback mechanism. ERb knockdown in hypoxic PAECs also decreased expression of the HIF inhibitor prolyl hydroxylase 2 (PHD2), whereas ERb activation increased PHD2 and decreased both HIF-1a and HIF-2a, suggesting that ERb regulates the PHD2/HIF-1a/HIF-2a axis during hypoxia. Whereas hypoxic wild-type or ERa knockout mice treated with E2 demonstrated less pulmonary vascular remodeling and decreased HIF-1a after hypoxia compared with untreated hypoxic mice, ERb knockout mice exhibited increased HIF-2a and an attenuated response to E2 during hypoxia. Taken together, our results demonstrate a novel and potentially therapeutically targetable mechanism whereby hypoxia, via HIF-1a, increases ERb expression and the E2-ERb axis targets PHD2, HIF-1a, and HIF-2a to attenuate HPH development.
Pulmonary hypertension (PH) encompasses a heterogeneous group of pulmonary vascular disorders characterized by increased vasoconstriction and aberrant muscularization of the pulmonary arteries (PAs) that lead to increased right ventricular afterload and, if left untreated, right ventricular failure and death (1) (2) (3) . Several forms of PH are characterized by sexual dimorphism. For example, hypoxiainduced PH (HPH), one of the most common forms of PH worldwide (4) (5) (6) , is less common and less severe in females (reviewed in Reference 7). On the other hand, pulmonary arterial hypertension (PAH), a progressive vasculopathy characterized by uncontrolled endothelial proliferation, obliterative PA lesions, and markedly elevated PA pressures, exhibits a female/male ratio that ranges from 1.4 to 4.1:1 (reviewed in Reference 7). These disparate observations have been attributed to dichotomous and tissue-dependent effects of 17b-estradiol (E2) and its receptors (estrogen receptor a [ERa] and ERb). For example, although E2 may have detrimental effects on the pulmonary vasculature in the context of a BMPR2 mutation (8, 9) , it has favorable ERdependent effects on pulmonary vascular tone and PA endothelial cell (PAEC) homeostasis in hypoxic conditions (10) (11) (12) (13) . Interestingly, E2's vasculoprotective effects on PAECs are not observed during normoxic conditions, indicating that E2 exerts specific actions during hypoxia that may not be active during nonhypoxic conditions. Further studies of the specific effects of hypoxia on E2 signaling in the pulmonary vasculature are therefore of crucial importance, as such investigations may 1) identify potential novel therapeutic targets for HPH and PH induced by chronic lung diseases, and 2) elucidate whether alterations in the E2-ER axissimilarly to recently identified alterations in estrogen metabolism (14, 15 )-contribute to the predisposition of females for PAH. Given our recently reported observations of hypoxia-specific and ER-mediated protective E2 signaling in HPH (10, 16) , we aimed to identify whether and how hypoxia affects ER expression and function in the pulmonary vasculature.
ERa and ERb (encoded by the genes Esr1 and Esr2, respectively) are proteins that belong to the nuclear-receptor superfamily of transcription factors and are expressed in both sexes (17, 18) . Two subtypes exist, both of which are expressed in the histologically normal lung, with ERb purportedly being more abundant than ERa (19) (20) (21) (22) . In addition to differences in tissue expression patterns, the two ERs also differ in their biological functions (21) (22) (23) (24) . For instance, in the setting of breast and prostate cancer, ERa mediates proproliferative effects and ERb mediates antiproliferative signaling (25) (26) (27) (28) . Interestingly, ERb exhibits relevant effects in PAECs. Specifically, ERb mediates E2-induced increases in endothelial nitric oxide synthase activity and prostacyclin synthesis in fetal bovine PAECs (29, 30) , and attenuates ERK1/2 (p42/44 MAPK) activation in hypoxic rat PAECs (10) . Administration of a selective ERb agonist replicates E2's inhibitory effects on hypoxic pulmonary vasoconstriction in isolated rat PA rings, and this effect is mediated in a nitric oxide-and endothelium-dependent manner (13) . Lastly, in a rat model of HPH, E2-mediated decreases in pulmonary vascular remodeling were attenuated after cotreatment with a selective ERb antagonist (10) .
These findings implicate a unique pathway of ER-dependent signaling during hypoxia that inhibits pulmonary vascular remodeling. We sought to investigate whether and how hypoxia affects ER expression and function in vitro and in vivo. We demonstrate for the first time that hypoxia upregulates ERb expression in isolated PAECs as well as in the pulmonary vasculature, and that this increase is dependent on hypoxia-inducible factor 1a (HIF-1a). Furthermore, we provide the first evidence demonstrating that ERb decreases both HIF-1a and HIF-2a in vitro and in vivo, and is necessary for E2's vasculoprotective effects in a murine model of HPH. This novel role of ERb in regulating HIF-2a is of particular relevance because dysregulated HIF-2a signaling has recently been reported to be a potent driver of the formation of obliterative lesions in PH (31, 32) . Finally, we provide evidence that ERb stimulates expression of the HIF-a inhibitor prolyl hydroxylase 2 (PHD2) in PAECs, thus identifying attenuation of HIF-1a and HIF-2a signaling as a novel mechanism of E2 action in the pulmonary vasculature. Parts of this study have been previously reported in abstract form (33, 34) .
Methods
Please refer to the data supplement for details regarding the materials and methods used in this work.
Animal Care
The animal studies were approved by the Indiana University School of Medicine Institutional Animal Care and Use Committee, and adhered to the National Institutes of Health guidelines for the care and use of laboratory animals under the Animal Welfare Act.
In Vivo Studies
The HPH model has been described previously (10) . Male Sprague-Dawley rats (Charles River) or wild-type (WT), Esr1
2/2
, and Esr2 2/2 C57BL/6 mice (Jackson Laboratories) were exposed to 2-3 weeks of hypobaric hypoxia, respectively. A subgroup of mice were treated with E2 (75 mg/kg/d via subcutaneous pellets [10] ; Innovative Research of America) for the duration of hypoxia exposure.
In Vitro Studies
Primary rat PAECs (from Drs. Troy Stevens and Diego Alvarez, University of South Alabama) or human PAECs (Lonza) were exposed to hypoxia (1% O 2 ) using an InvivO 2 hypoxia workstation (Ruskinn, Inc.) as described previously (10) . Control cells of identical passage/confluence were grown concomitantly under room-air conditions. To verify that no detectable or only minimal amounts of E2 were present in the culture media, E2 concentrations were quantified via ELISA (Calbiotech) and by comparing levels with those from E2-treated media (see Fig. E1 in the data supplement). Cells were treated with deferoxamine (DFO; 10-100 mM; Sigma-Aldrich) for 24 hours in room air or with the selective ERb agonist diarylpropionitrile (DPN; 1-100 nM; Tocris) for 48 hours at 1-5% O 2 . Cells were transfected using Lipofectamine 2000 with siHIF-1a or siERb (ThermoFisher) for 24 hours and exposed to hypoxia for 24-48 hours.
Immunocytochemistry
Rat or human PAECs were seeded on gelatin-coated coverslips and exposed to room air or hypoxia. The EC phenotype was confirmed ( Figure E2 ). Primary antibodies against ERa or ERb (1:200; Santa ORIGINAL RESEARCH Cruz) were used. Alexa Fluor 488 conjugated anti-rabbit secondary antibody (1:200; ThermoFisher) and DAPI (ThermoFisher) mounting media were used. Ten fields per slide were taken using a Nikon microscope at 40 3 . ER expression was quantified as the average megapixel intensity per number of nuclei by ImageJ (National Institutes of Health).
Immunohistochemistry
Lung sections were stained with ERa (1:500, Santa Cruz) or ERb (1:10; Dako) and quantified using Metamorph software. WT, Esr1 2/2 , and Esr2 2/2 mouse lungs were stained for a-smooth muscle actin (1:500; Abcam). Quantification was performed as previously described (10) .
Western Blotting
Tissue/cell lysis was performed as previously described (10) . The following antibodies were used: ERa (1:1,000; Santa Cruz), ERb (1:1,000; Santa Cruz), HIF-1a and HIF2-a (1:1,000; Novus Biological), PHD2 (1:1,000; Abcam), and vinculin (1:5000; Calbiochem). Densitometry was performed via ImageJ.
Real-Time qRT-PCR
Total RNA was isolated from rat and human PAECs using the RNeasy Plus Mini Kit (Qiagen), and 1 mg total RNA was reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad). TaqMan gene expression assays for Esr1, Esr2, and 18S (ThermoFisher; for assay IDs, see the data supplement) were used. Changes in mRNA expression were determined by the comparative CT (2 2ΔΔC T ) method and expressed as the fold change compared with normoxic controls.
Statistical Analyses
Results are expressed as means 6 SEM. At least three independent experiments (run in duplicates) were performed for all in vitro studies. Statistical analyses were performed with GraphPad Prism 6 (La Jolla, CA Figure 2D ), suggesting that the hypoxiainduced increase in ERb is mediated by a transcriptional mechanism. This increase was specific to ERb, as similar increases in ERa mRNA expression were not observed ( Figure 2D ).
To corroborate these findings, we cultured human primary PAECs under hypoxic conditions for 24 or 72 hours, and As in the rat PAECs, hypoxia selectively and time dependently increased ERb (but not ERa) expression, with a trend toward an increase at 24 hours and a significant 25% increase at 72 hours ( Figures 3A and 3B) . As in the rat PAECs, immunocytochemistry studies suggested that the hypoxia-induced increase in ERb abundance was paralleled by a change in ERb's cellular localization pattern consistent with translocation to the nucleus ( Figures 3A and 3C ). In fact, 80% of the ERb-positive cells colocalized with DAPI at 24 hours, and this was maintained even at 72 hours. Finally, we quantified the changes in ERb expression using real-time RT-PCR. Similar to what was observed with rat PAECs, ERb, but not ERa, mRNA was significantly increased at 24 hours (but not at the earlier time point of 4 h; Figure 3D ), suggesting that the hypoxiainduced increase in ERb is transcriptionally regulated. Interestingly, we also observed hypoxic induction of ERb, but not ERa, protein in human pulmonary microvascular endothelial cells (PMVECs; Figure E4 ) and pulmonary smooth muscle cells (data not shown) at 72 hours, indicating that the specific hypoxic regulation of ERb is relevant to multiple cell types/phenotypes in the pulmonary vasculature. Taken together, these data indicate that hypoxia 1) selectively increases ERb mRNA and protein in cultured primary PAECs, and 2) results in nuclear translocation of ERb, suggesting that this receptor has biologically relevant effects in the context of hypoxia.
Normoxic HIF-a Stabilization Is Sufficient to Increase ERb in Rat PAECs
We next sought to determine whether the hypoxia-induced increase in rat PAEC ERb expression is driven by HIF-1a, a master regulator of hypoxia-driven responses (35) . containing germline null mutations for ERa or ERb, respectively) and WT mice with E2 (75 mg/kg/day [10] ), and exposed them to 3 weeks of hypoxia (Patm = 362 mm Hg). An additional group of untreated WT mice were placed in hypoxia to serve as controls. As previously noted in chronically hypoxic rats, compared with hypoxic WT controls, E2 treatment in WT mice significantly decreased hypoxiainduced pulmonary vascular remodeling by 40% ( Figures 7A and 7B) . Importantly, this , mice ( Figures 7A  and 7B ), suggesting that ERb is required for E2 to attenuate hypoxia-induced pulmonary vascular remodeling. Contrary to our hypothesis, PHD2 was not affected by E2 or loss of ERa or ERb ( Figures 7C  and 7D ), suggesting that PHD2 is not solely regulated by E2-ER signaling. Alternatively, it is possible that E2-ER-mediated changes in PHD2 expression in PAECs in vivo were not captured at the time point investigated, or were masked by surrounding tissue in whole-lung homogenates. On the other hand, E2 treatment in hypoxic WT mice tended to decrease lung HIF-1a and HIF2a expression (Figures 7C, 7E, and 7F) , and in the case of HIF-1a, resulted in a significant 50% decrease in E2-treated Esr1 2/2 mice (where E2 signaling occurs through ERb; Figures 7C and 7E) . However, E2 did not lower HIF-1a abundance in Esr2 2/2 mice (where E2 signaling occurs through ERa; Figures 7C  and 7E ). In parallel, E2 treatment led to increased HIF-2a expression in Esr2 2/2 mice ( Figures 7C and 7F ). This suggests that ERb is required for E2 to decrease HIF-2a and HIF-1a expression. However, in the latter case, this effect can only occur in the absence of ERa, indicating that 1) ERa has effects opposite to those of ERb and actually increases HIF-1a, and 2) ERa and ERb compete with each other for E2 binding. Taken together, these studies demonstrate that ERb is required for E2 to attenuate hypoxia-induced pulmonary vascular remodeling, is necessary for E2 to decrease lung HIF-a expression, and prevents increases in lung HIF-2a expression.
Discussion
Our studies reveal that ERb, but not ERa, is upregulated in hypoxic rat lung, cultured hypoxic rat and human conduit PAECs, and PMVECs. We show for the first time that HIF-a chemical stabilization with DFO is sufficient to induce ERb expression and that knockdown of HIF-1a by siRNA reduces ERb expression in hypoxic PAECs, identifying that the hypoxia-induced increase in ERb expression occurs via a HIF-a-dependent mechanism. Additionally, we provide novel evidence suggesting that HIF-2a is downregulated and PHD2 is upregulated by ERb in vitro. siRNA directed against ERb leads to the robust upregulation of HIF-2a and downregulation of PHD2 in hypoxic PAECs, and treatment with the ERb agonist DPN upregulates PHD2 expression and decreases HIF-1a and HIF-2a in a dose-dependent manner. Lastly, we demonstrate that ERb is necessary for E2 to attenuate hypoxia-induced pulmonary vascular remodeling, decrease lung HIF-1a, and prevent increases in HIF-2a expression. However, the decrease in HIF-1a in vivo only occurred in the absence of ERa. Taken together, these novel data implicate ERb as a mediator of protective E2 signaling in the hypoxic pulmonary vasculature. A schematic of the putative interaction among hypoxia, ERb, HIF-1a, HIF-2a, and PHD2 in the pulmonary vasculature is provided in Figure E6 .
HPH is prevalent globally; it affects millions of people living at high altitude and millions of patients afflicted with a wide spectrum of chronic lung disease and sleep-disordered breathing (5). HPH is characterized by significant pulmonary vascular remodeling that may culminate in right ventricular failure and death (4, 38) . Although it occurs much more frequently than PAH (39) , no specific treatment for HPH exists. In fact, therapeutics used for PAH frequently worsen oxygenation in 2/2 (solid triangles), and E2-treated Esr2 2/2 (solid inverted triangles) mice exposed to chronic hypobaric hypoxia (Patm = 362 mm Hg; equivalent to 10% FI O 2 ; 3 wk). Note the decrease in vascular wall thickness (arrowheads) in E2-treated WT and Esr1 2/2 mice, but not in E2-treated Esr2 2/2 mice compared to WT controls. Scale bars = 50 mm. (B) Quantification of the wall thickness of small-and medium-sized pulmonary arteries (less than 200 mM). (C) PHD2, HIF-2a, and HIF-1a protein expression in mouse lung homogenates from WT, E2-treated WT, E2-treated Esr1 2/2 , and E2-treated Esr2 2/2 mice exposed to chronic hypobaric hypoxia. (D-F) Expression levels of lung PHD2, HIF-2a, and HIF-1a quantified by densitometry; n = 4-5 per group. Scatterplots include means 6 SEM. *P , 0.05 versus WT; # P , 0.05 versus WT 1 E2;^P , 0.05 versus Esr1 2/2 (one-way ANOVA with post hoc Tukey's test). E2 = 17b-estradiol.
HPH (reviewed in References 7 and 43).
A better understanding of the effects of E2 and its receptors in the hypoxic pulmonary vasculature could provide the rationale and basis for future studies focused on developing novel therapeutic strategies for HPH. We previously demonstrated that E2 attenuates HPH via an ER-dependent mechanism (10), and recently expanded upon that finding by discovering an ERdependent genome in lungs from HPH rats (16) . Of note, our previous data showed that E2 exerts specific antiproliferative effects during hypoxia that are not evident during normoxia (10) . For example, E2-ER dependently decreased bromodeoxyuridine uptake and vascular endothelial growth factor secretion in hypoxic rat PAECs, but not in PAECs grown in room air. Our current data expand upon these findings and suggest that hypoxia-enabled increases in ERb expression may allow for E2 to exert its hypoxia-specific effects. Such a finding may explain why E2 has consistently been shown to be protective in hypoxia models of PH, whereas its effects in other types of PH have been less consistent (reviewed in Reference 7).
If ERb signaling can be protective in the pulmonary vasculature, this raises the possibility that alterations in ERb signaling may contribute to the female predominance noted in PAH. Of note, SNPs in ESR2 2/2 have been associated with LV structural differences in women with hypertension (44) and with increased arterial stiffness in Framingham Offspring Study participants (45) . This suggests that genetic alterations in ESR2 2/2 could also contribute to abnormalities in the pulmonary vasculature. Alternatively, in the absence of hypoxiaenabled increases in ERb expression, E2's protective signaling pathways may not be engaged, allowing for the development of pulmonary vascular disease, especially in the context of otherwise predisposing conditions for PAH development (e.g., genetic abnormalities and environmental exposures).
To the best of our knowledge, our studies are the first to implicate HIF-1a as a regulator of ERb in PAECs. Given that HIF-1a is a key regulator of hypoxiamediated effects, this finding is not entirely surprising. Our findings are consistent with results from studies in HEK293 cells, which demonstrated that HIF-1a transcriptionally activates ERb expression in the absence of E2, and the addition of E2 did not further enhance the upregulation of ERb (46) . Subsequent studies in other cell types have linked HIF-1a to the induction of ERb independently of E2 (47) (48) (49) . For instance, in human ER-positive breast cancer cells, hypoxia stimulated ERb expression and reduced ERa expression (48) , whereas in human stromal cells isolated from patients with endometriosis, hypoxia strongly induced ERb (47) , both in the absence of E2. Additionally, steroid receptor coactivator-1 and CREB-binding protein comprise part of the HIF-1a transcriptional coactivator complex and can promote ERb transcription in the absence of E2 (49) . Building on these observations, we performed PROMO and TRANSFAC in silico promoter analyses, which identified two putative HIF-1a binding sites in the ESR2 promoter (Ensembl ENSG00000140009) to be validated in future studies. Interestingly, we did not observe a significant increase in ERb mRNA expression until 16 hours (human PAECs) or 24 hours (rat PAECs) after hypoxia. One explanation for this slow upregulation is that because ERb expression is regulated by multiple coactivators and corepressors, there may be a transcriptional repressor complex at the ERb promoter upon the first, acute induction of HIF-1a due to hypoxia that is not present at a later, chronic hypoxia time point. Finally, we cannot completely rule out that the trace amounts of E2 detected in rat PAEC media ( Fig. E1 ; likely arising as a result of endogenous PAEC E2 synthesis via aromatase [50] ) activated ERb. However, this seems unlikely, as no E2 was detected in human PAEC media, yet hypoxia increased ERb expression and induced its translocation in this cell type as well. Together, these data suggest that ERb, independently of the presence of E2, is encoded by a hypoxia-responsive gene.
The finding that ERb in turn regulates HIF-1a and HIF-2a in vitro and in vivo reveals a novel and potentially therapeutically targetable mechanism of action in the hypoxic pulmonary vasculature that may explain in part why E2 attenuates HPH and why females are protected against the development of HPH. This putative negative-feedback loop of ERb on HIF-a likely occurs via direct binding of HIF-1a to ERb, followed by the nuclear translocation of ERb and binding to estrogen response elements of target genes. Interestingly, at least one study has shown that the ERb protein is able to bind directly to HIF-1a (46) . Alternatively, hypoxia could indirectly facilitate ERb nuclear translocation via direct activation of ERb by a HIF-1a-induced growth factor, e.g., epidermal growth factor (51). The negative-feedback mechanism we identified is consistent with data from the oncology literature, which demonstrates that ERb inhibits HIF-1a transcriptional activity and promotes its proteasome degradation in prostate cancer cells (52) . On the other hand, to the best of our knowledge, we are not aware of any prior data demonstrating that ERb decreases HIF-2a. This is of particular importance because dysregulated HIF-2a signaling has been linked to the formation of obliterative pulmonary vascular lesions in PH (32) . However, the effects of ERb on HIF-1a and HIF-2a were not clear-cut. At 24 hours of ERb knockdown, both HIF-1a and HIF-2a were decreased rather than increased, suggesting a time dependence of ERb effects on these transcription factors. In addition, ERb knockdown did not lead to increased HIF1a at the 48-hour time point. This phenomenon may be explained by competing effects of ERa and ERb on HIF expression: ERa (or another, as yet unidentified factor) may compensate for the loss of ERb and repress HIF-a. On the other hand, the finding that selective ERb activation decreased both HIF-1a and HIF-2a clearly indicates that ERb exerts inhibitory effects on these mediators.
The in vivo effects of E2 and ERb on HIF-a were complex. E2 did not statistically significantly decrease HIF-1a in hypoxic WT rats (even though there was a trend), and a significant decrease occurred only in E2-treated Esr1 2/2 mice. Although this could be the result of a type II error, it may also suggest that ERa increases HIF-1a. Specifically, ERa and ERb may have opposing effects on HIF-1a in vivo, allowing ERb to decrease HIF-1a only in the absence of ERa. Such a paradigm would be consistent with the known proproliferative effects of ERa in prostate cancer (28) and in PA smooth muscle cells (53) . An alternative hypothesis is that the absence of ERa increases the abundance of E2 at ERb, thus driving a more prominent ERb signal. This would suggest that ERa and ERb compete with each other for binding to E2. Such a scenario is likely, given that in the absence of ERb there is no increase in HIF-1a ( Figures 7C and 7F) . Our data suggest that the inhibitory effect of ERb on HIF-1a and HIF-2a may be mediated by PHD2. PHDs hydroxylate HIF-1a and HIF-2a, leading to von Hippel-Lindau protein-dependent ubiquitination and rapid proteasomal degradation (35) . Three main isoforms exist, with PHD2 being the most prominent isoform (36) . Interestingly, we found that ERb induces PHD2 in hypoxic PAECs. This may, in turn, downregulate HIF-1a and HIF-2a. This finding is supported by recently published data from prostate epithelial cells demonstrating that ERb promotes HIF-1a degradation by increasing PHD2 transcription and by identifying an estrogen response element in the PHD2 promoter (52) . Given the recent report that PHD2 expressed in PAECs protects against PAH development (32), our identification of PHD2 as a target of ERb is of particular interest, as it suggests a novel mechanism whereby E2 attenuates HPH development.
ORIGINAL RESEARCH
ERb may also inhibit HIF-1a and HIF-2a through PHD2-independent mechanisms. For example, ERb was shown to inhibit HIF-1a transcriptional activity via downregulation of ARNT (HIF-1b) (54) . In another study, ERb was shown to destabilize HIF-1a protein via proteasomal degradation (55) . It is possible that similar mechanisms regulate ERb's effects on HIF-1a in the hypoxic pulmonary vasculature. Future studies will focus on identifying the exact molecular mechanisms of ERb-mediated attenuation of HIF-1a and HIF-2a in the hypoxic lung and in hypoxic PAECs.
Our study has several limitations. First, although our in vitro data robustly identify PHD2 as a target of ERb, we did not detect any changes in PHD2 expression in Esr1 2/2 or Esr2 2/2 mice treated with E2. Although it is possible that PHD2 is not regulated by E2-ERb signaling in vivo, we consider it more likely that E2-ERbmediated changes in PHD2 expression in PAECs in vivo were not captured at the time point investigated, or were masked by surrounding tissue in whole-lung homogenates. This is supported by the observation that the effects we noted on HIF-1a and HIF-2a were robust in vitro as well as in vivo. Second, our in vitro studies used a severe level of hypoxia (1% O 2 ). This severe level of hypoxia can inhibit PHD2 activity at least acutely (at 4 h), but perhaps not chronically (36, 37, 56) , which could be a source of variability in our data; however, we were able to corroborate our DPN findings using less severe hypoxic conditions (5% O 2 ), during which PHD2 should be active ( Figure E3 ). Second, in our studies we used in vitro rat and human primary cells, and conducted in vivo studies in rats and mice; however, it should be noted we did not use human cells for all studies. Future investigations will focus on expanding upon these mechanisms in human PAECs and PMVECS, and in patients with HPH under less severe hypoxic conditions. Third, although we confirmed that hypoxia upregulates ERb in several cell types and in two species, we did not corroborate our mechanistic studies in human cells. We did, however, confirm the relevance of this signaling pathway in vivo, making the rat PAEC studies relevant. Mechanistic studies dissecting the interplay among HIFs, PHD, and ERb in PAECs from healthy donors and patients with PH are currently ongoing in our laboratory. To eliminate potentially confounding effects of estrogens or the estrous cycle on ER expression, we performed the current study in male animals, and therefore do not provide information on ER expression in hypoxic females. Similarly, our commercially obtained human PAECs and PMVECs were derived from male donors. Studies in females are currently underway, and a sex-specific comparison of ER expression will be the focus of future investigations. Lastly, our studies focused on hypoxia-induced changes in the pulmonary vasculature and are therefore relevant for HPH and WHO group 3 PH, but cannot necessarily be extrapolated to PAH. Given that HIF-1a, HIF-2a, and female sex play major roles in PAH development, the cross-talk among HIF-1a, HIF-2a, E2, and ERb in this disease needs to be explored further. The protective ERb signaling noted in hypoxia may be lost or altered in PAH.
In summary, we provide the first evidence of a novel HIF-1a-dependent hypoxia pathway that induces ERb, but not ERa, in PAECs and PMVECs. We show that the hypoxia-induced upregulation of ERb is specific to the lung and pulmonary vasculature, as evidenced by the decrease in ERb expression in the hypoxic RV and liver. We demonstrate that ERb induces expression of the HIF-a inhibitor PHD2 and decreases HIF-1a and HIF-2a expression in vitro. In vivo, ERb prevents increases in HIF-2a and is necessary for E2 to decrease lung HIF-1a and hypoxia-induced pulmonary vascular remodeling. Harnessing these pathways may facilitate the development of specific therapeutic strategies for patients with HPH and WHO group 3 PH, for whom there are no pharmacological treatment options, and help unravel the "estrogen paradox" in PAH. n Author disclosures are available with the text of this article at www.atsjournals.org.
